Breast Cancer

, Volume 1, Issue 1, pp 1–9 | Cite as

The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer: Meta-analysis of the first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC)

  • Osahiko Abe
Review Article


The first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC) were carried out in 6 regions of Japan from 1982 to 1985, and the results were subjected to meta-analysis.

Subjects consisted of Stage II and IIIa cases who underwent radical mastectomy with Brt + Ax or more extensive resection for primary breast cancer.

Regimen A consisted of tegafur (Futraful: FT) alone at 600 mg/day, and regimen B of FT at 600 mg/day with tamoxifen (TAM) at 20 mg/day. The duration of the treatment was one year in the Tohoku and Kinki regions, and 2 years in the other 4 regions.

Meta-analysis by Peto’s method showed an odds reduction of 20 ± 7% (logrank test:P = 0.0069) for the 5-year overall survival rate in 4740 eligible patients, and 25 ± 6% (logrank test: P>0.0001) for the 5-year disease-free survival rate. The odds reductions were both statistically significant, indicating that the adjuvant chemoendocrine therapy was effective. Subset analysis of data on 5 - year disease-free survival showed that FT plus TAM therapy was better in ER-positive and postmenopausal patients, whether axillary lymph nodes were positive or negative.

Key words

Meta-analysis Postoperative adjuvant chemoendocrine therapy Breast cancer Tegafur (Futraful) Tamoxifen 



Adjuvant chemoendocrine therapy for breast cancer




CycIophosphamide, adriamycin, 5-FU


Cyclophosphamide, methotrexate, 5-FU




Estrogen receptors




Mitomycin C




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Yoshida M, Murai H, Miura S: Post-operative chemotherapy with oral cyclophosphamide in breat cancer (UICC 73-047).J Jap Soc Cancer Ther 18 (8):2166, 1982.Google Scholar
  2. 2).
    Yamase H, Akita Y, Takaesu Y,et al: Long term results of post-operative adjuvant chemotherapy with mitomycin C in breast cancer.J Jap Soc Cancer Ther 17 (8):2115, 1982.Google Scholar
  3. 3).
    Koyama H, Wada T, Takahashi T,et al: Surgical adjuvant chemotherapy with mitomycin C and cyclophospamide in Japanese patients with breast cancer.Cancer 46:343–348, 1980.CrossRefGoogle Scholar
  4. 4).
    Ansfield F, Kallas GJ, Sington JP: Phase I -II studies of oral tegafur (ftorafur).J Clin Oncol 1:107–110, 1983.PubMedGoogle Scholar
  5. 5).
    Adachi I: Endocrine therapy for advanced breast cancer evaluated by the site of metastasis; Therapeutic results of chemotherapy and life prolonging effect.Jpn J Cancer Chemother 8(Suppl):72–78, 1981.Google Scholar
  6. 6).
    Chikada C, Niitani H, Sakauchi N,et al: Oral treatment withN 1-(2’-furanidyl)-5-fluorouracil (FT-207).Jpn J Cancer Clin 19:435–439, 1973.Google Scholar
  7. 7).
    Wada T, Koyama H, Nishizawa M,et al: Chemoendocrine therapy in advanced breast cancer; Combined therapy with tamoxifen plus FT 207.J Jap Soc Cancer Ther 16 (1):51–55, 1981.Google Scholar
  8. 8).
    Buyse M: Potential and pitfalls of randomized clinical trials in cancer research.Cancer Surv 8:91–105, 1989.PubMedGoogle Scholar
  9. 9).
    Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy.Lancet 339:1–15, 71–85, 1992.Google Scholar
  10. 10).
    Sakamoto G: Characteristics and future of breast cancer in Japanese population.Jpn J Breast Cancer 2 (3):327–338, 1987.Google Scholar
  11. 11).
    Early Breast Cancer Trialists’ Collaborative Group: Treatment of early breast cancer, Vol. 1; Worldwide evidence, 1985–1990, Oxford University Press, Oxford, 1990.Google Scholar
  12. 12).
    Glick JH: Meeting highlights; Adjuvant therapy for breast cancer.J NCI 84:1479–1485, 1992.Google Scholar
  13. 13).
    Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen.Pharmacol Ther 25:127–205, 1984.PubMedCrossRefGoogle Scholar
  14. 14).
    Abe O, Izuo M, Enomoto K,et al: Study of adriamycin in advanced and recurrent breast cancer, Part 2; Multicentered clinical study of CAF therapy in 18 medical centers.Jpn J Cancer Chemother 9 (5):866–873, 1982.Google Scholar

Copyright information

© The Japanese Breast Cancer Society 1994

Authors and Affiliations

  • Osahiko Abe
    • 1
  1. 1.Sr Luke’s International HospitalChuo-ku, Tokyo 104Japan

Personalised recommendations